Solventum has launched the V.A.C.® Peel and Place Dressing in the United Kingdom, an innovative all-in-one solution for negative pressure wound therapy (NPWT). Designed to simplify application and improve patient comfort, the dressing can be applied in under two minutes¹ and worn by patients for up to seven days².

The V.A.C.® Peel and Place Dressing builds on the success of V.A.C.® Therapy, which has been used globally for nearly three decades to treat over 10 million wounds. This new product aims to make NPWT more accessible and less painful for patients while also streamlining workflows for healthcare providers.

Dr. Mark Portou, consultant vascular surgeon at Royal Free London NHS Foundation Trust, shares his experience:

“We have instantly doubled our post-discharge wound NPWT clinic capacity by reducing individual clinic visits by half. The up-to-7-day wear time enables us to see these patients only once per week, reducing inconvenience, disruption and cost to the patients.”

The V.A.C.® Peel and Place Dressing's integrated design eliminates the need for separate foam and adhesive components, reducing application time and training requirements. It also features a non-adherent layer to minimize tissue ingrowth, making dressing changes less painful.

Dot Weir, a wound care nurse with over 40 years of experience, highlights the benefits for patients and clinicians:

“Being able to quickly and safely apply the dressing to deeper and more varied types of wounds and for it to stay in place longer means fewer dressing changes, home care visits and clinic trips. This allows patients to get back to their lives more quickly.”

The V.A.C.® Peel and Place Dressing was previewed at the 35th European Wound Management Association (EWMA) Congress in Barcelona and is now available in the United Kingdom.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Forward-Looking Statements

This news article contains forward-looking information about Solventum's financial results, estimates, product launches and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to Solventum's reputation or its brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events, including the divestiture of our Purification and Filtration business or the acquisition of Acera Surgical; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property rights; (21) pension and postretirement obligation liabilities; (22) any failure by 3M Company ("3M") to perform any of its obligations under the various separation agreements entered into in connection with the separation of Solventum from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off; (24) a determination by the IRS or other tax authorities that the Spin-Off or certain related transactions should be treated as taxable transactions; (25) financing transactions undertaken in connection with the Spin-Off and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum's estimates; (27) the impact of the Spin-Off on Solventum's businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on Solventum's resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties, and (28) any delay or failure to close the acquisition of Acera Surgical.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

Disclosures

Mark Portou and Dot Weir are consultants and speakers for Solventum.

References:

¹In a simulated use test with 12 nurse and surgeon users. 3M™ V.A.C.® Peel and Place Dressing took on average, 01:48 to apply whereas 3M™ traditional NPWT foam dressing and hybrid acrylic-silicone drape took on average, 04:40 to apply (p<0.01, Wilcoxon signed rank test). SAT-MTF-05-995965 Marketing study for 3M V.A.C. Peel and Place dressing. 2023.

²SAT-BSER-05-869347 VAC Peel and Place BSER. 510(k) K222859.